Indeed, in animal models ofinsulin resistance and diabetes, rexinoids have been shown tohave beneficial glucose-lowering, insulin-sensitizing, andantiobesity effects, while at the same time raising triglyceride(TG) levels and suppressing the thyroid hormone axis, sideeffects that have limited the development of these compounds astherapeutic agents for the treatment of type 2 diabetes andinsulin resistance. This evidence concerns the gene INS and type 2 diabetes mellitus.